# Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

> **NCT06171152** · EARLY_PHASE1 · SUSPENDED · sponsor: **University of Chicago** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Sclerosis
- Long COVID
- Long Covid19
- Obese
- Obesity
- Obesity, Morbid
- Acute Leukemia in Remission

## Interventions

- **DRUG:** Liraglutide Pen Injector [Saxenda]
- **OTHER:** Medication Diary

## Key facts

- **NCT ID:** NCT06171152
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-01-26
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Study pending amendment
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06171152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06171152, "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06171152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*